Recruitment

Recruitment Status
Enrolling by invitation
Estimated Enrollment
Same as current

Summary

Conditions
Parkinson's Disease
Type
Interventional
Phase
Phase 1
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 40 years and 80 years
Gender
Both males and females

Description

Parkinson's disease (PD) is a neurodegenerative movement disorder?which mainly shows up in the elderly. And there is as yet no effective drug treatment. Umbilical cord derived mesenchymal stem cells (UC-MSCs) derived from mesoderm owns strong proliferation ability and multiple differentiation potent...

Parkinson's disease (PD) is a neurodegenerative movement disorder?which mainly shows up in the elderly. And there is as yet no effective drug treatment. Umbilical cord derived mesenchymal stem cells (UC-MSCs) derived from mesoderm owns strong proliferation ability and multiple differentiation potential. The investigators used UC-MSCs via intravenous infusion to treat PD. With different durations of follow-up, the investigators cleared therapeutic effect, the quality of life and prognostic implications of UC-MSCs on PD through the Unified Parkinson's Disease Rating Scale (UPDRS), revised Hoehn-Yahr?H-Y? staging, Mini-Mental State Examination (MMSE), Hamilton depression scales 24 (HAMD 24), Hamilton Anxiety Scale 14 (HAMA 14) and Clinical Global Impression (CGI). In this research, the investigators seek new therapeutic approaches for PD, and provide clinical evidences for the clinical application of UC-MSCs in the future.

Tracking Information

NCT #
NCT03550183
Collaborators
Not Provided
Investigators
Study Chair: Xiqing Chai, Doctor Hebei Chemical & Pharmaceutical College Study Director: Ping Gu, Doctor The First Hospital of Hebei Medical University Study Director: Hongxu Chen, Master The First Hospital of Hebei Medical University
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024